Загрузка видео...

Не удалось загрузить видео

Возникла проблема при загрузке этого видео. Это может быть связано с временными проблемами сети или видео может быть недоступно.

На главную

Get Wegovy® with Hims, plus access to provider-led care and ongoing support designed around your lifestyle. Why Hims? • FDA-approved GLP-1 pill and pens available • Medication as low as $149/mo—membership fee of $39 for first month, $149 thereafter • 100% online

hims

32,124 subscribers

2,683,697 просмотров • 1 месяц назад •via X (Twitter)

Здоровье и велнес Финансы

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Customer access should move at the same speed as innovation. When the healthcare industry works together to reach individuals, it does. Since last week, thousands of people have signed up for our Wegovy® waitlist. Starting today, eligible Hims & Hers customers can start their journeys with Novo Nordisk’s FDA-approved Wegovy® Pill & Wegovy® Pen and partner with their provider on a comprehensive weight loss program designed to help them achieve their goals. We take our role as the largest global consumer health platform seriously, and I can’t wait to keep finding ways to make sure everyone can access the tools they need to feel great. Read more below from Dr. Craig, our Head of Weight Loss, on what’s available today. (And if you’re starting your Wegovy journey with us today, tag me and tell me how it’s going!) More details, including important info, here:

Customer access should move at the same speed as innovation. When the healthcare industry works together to reach individuals, it does. Since last week, thousands of people have signed up for our Wegovy® waitlist. Starting today, eligible Hims & Hers customers can start their journeys with Novo Nordisk’s FDA-approved Wegovy® Pill & Wegovy® Pen and partner with their provider on a comprehensive weight loss program designed to help them achieve their goals. We take our role as the largest global consumer health platform seriously, and I can’t wait to keep finding ways to make sure everyone can access the tools they need to feel great. Read more below from Dr. Craig, our Head of Weight Loss, on what’s available today. (And if you’re starting your Wegovy journey with us today, tag me and tell me how it’s going!) More details, including important info, here:

andrewdudum

94,408 просмотров • 6 месяцев назад

Get access to Ozempic, Wegovy, or Zepbound—now prescribed online through Ro. See if GLP-1 medication is right for you by answering questions about your health, lifestyle, and goals. See full important safety information, including boxed warning:

Get access to Ozempic, Wegovy, or Zepbound—now prescribed online through Ro. See if GLP-1 medication is right for you by answering questions about your health, lifestyle, and goals. See full important safety information, including boxed warning:

Ro

10,825,345 просмотров • 2 лет назад

Get access to weight loss medication— prescribed online through Ro. See if GLP-1 medication is right for you by answering questions about your health, lifestyle, and goals. See safety info link at end of video.

Get access to weight loss medication— prescribed online through Ro. See if GLP-1 medication is right for you by answering questions about your health, lifestyle, and goals. See safety info link at end of video.

Ro

1,785,170 просмотров • 1 год назад

🚨 $HIMS HOUSE - NEW EPISODE!! Sam Koppelman - Co-founder of Hunterbrook Why he believes Andrew Dudum "wiped the floor with Novo", the peptides opportunity, and Hunterbrook's current $HIMS position 👀. We've wanted to have Sam on the show for over a year now, so it was fun to finally chat. Thanks again Sam! 02:39 - Hims x Novo are back! 07:40 - Why Dudum "wiped the floor" with Novo 11:38 - The semaglutide pill controversy 13:48 - Branded vs compounded GLP-1s 16:32 - Eli Lilly next? 17:36 - FDA enforcement since Makary 21:31 - Why peptides could be HUGE 30:57 - Hims subscriber growth and outlook 33:18 - Ro vs Hims 35:45 - Hunterbrook's current Hims position Not financial, legal, or medical advice

🚨 $HIMS HOUSE - NEW EPISODE!! Sam Koppelman - Co-founder of Hunterbrook Why he believes Andrew Dudum "wiped the floor with Novo", the peptides opportunity, and Hunterbrook's current $HIMS position 👀. We've wanted to have Sam on the show for over a year now, so it was fun to finally chat. Thanks again Sam! 02:39 - Hims x Novo are back! 07:40 - Why Dudum "wiped the floor" with Novo 11:38 - The semaglutide pill controversy 13:48 - Branded vs compounded GLP-1s 16:32 - Eli Lilly next? 17:36 - FDA enforcement since Makary 21:31 - Why peptides could be HUGE 30:57 - Hims subscriber growth and outlook 33:18 - Ro vs Hims 35:45 - Hunterbrook's current Hims position Not financial, legal, or medical advice

Hims House

67,972 просмотров • 6 месяцев назад

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.

CBS News

19,903 просмотров • 5 месяцев назад

🚨 WHAT IS $HIMS MOAT IF ANYONE CAN LAUNCH A TELEHEALTH STARTUP OVERNIGHT? Today I'm joined by Eli Dorf, founder of Bask Health, the software platform that powers telehealth brands from launch to payments to pharmacy fulfillment. We discuss $HIMS' real competitive advantages, the rise of the first 2-person billion-dollar telehealth brand (MEDVi), whether Hims should build a wearable, the future of GLP-1s and peptides, and whether Ro will go public. Awesome conversation -- huge thanks to Eli for joining the show. 02:18 - What Bask Health does 03:19 - Launching a telehealth brand overnight 07:21 - Can anyone copy Hims? 14:28 - Bask's business model 16:28 - Fragmentation hits telehealth margins 19:48 - Medvi's cautionary tale 21:56 - What are Hims' real moats 25:29 - Data, AI, and wearables 26:39 - Should Hims sell hardware? 30:15 - FDA pressure on GLP-1s 33:44 - Peptides as the next GLP-1 moment 36:48 - Payment processing and LegitScript 41:05 - Why peptide trust matters 43:52 - The health super-app race 47:44 - Ro vs Hims 50:45 - Will Ro go public? Not financial, legal, or medical advice

Hims House

59,240 просмотров • 4 месяцев назад

Mark your calendar. We're launching our 🍸 Ridiculously Exclusive 🍸 membership on 12.02.25. Honestly, it's not for everyone. It was built and designed for those who want more than the usual. The membership gives you up to 4% cashback on all your purchases, $0 fees on selected transactions, and priority support for $20/month. We're keeping it ridiculously small. Only 100 people can get access. First come, first served. After we hit 100, you'll join a waiting list with people from all around the world. We'll open more spots gradually.

Mark your calendar. We're launching our 🍸 Ridiculously Exclusive 🍸 membership on 12.02.25. Honestly, it's not for everyone. It was built and designed for those who want more than the usual. The membership gives you up to 4% cashback on all your purchases, $0 fees on selected transactions, and priority support for $20/month. We're keeping it ridiculously small. Only 100 people can get access. First come, first served. After we hit 100, you'll join a waiting list with people from all around the world. We'll open more spots gradually.

UGLYCASH

10,167 просмотров • 10 месяцев назад

We are a 24/7 gym designed for your total lifestyle. Train anytime, day or night, then unwind at our Game Hub with friends, colleagues, and family. Enjoy free pool access as a member, plus two complimentary massage sessions every month to relax and recover your muscles. #fitnessandfun #lifestylefitness #fitfam #workout #dmayorfitness

We are a 24/7 gym designed for your total lifestyle. Train anytime, day or night, then unwind at our Game Hub with friends, colleagues, and family. Enjoy free pool access as a member, plus two complimentary massage sessions every month to relax and recover your muscles. #fitnessandfun #lifestylefitness #fitfam #workout #dmayorfitness

D MAYOR FITNESS & GAME HUB

16,370 просмотров • 7 месяцев назад

Today, we’re taking another step in making it easy to get proactive about your health. Introducing the Hims & Hers Multi-Cancer Test by Galleri®. By combining innovation from GRAIL and the ease of our platform, we’re giving you a way to screen for a signal for 50+ types of cancer in a single blood test. Our Chief Medical Officer, Dr. Pat Carroll, has spent decades as a family physician and has seen the difference earlier access to powerful technology can make for people everywhere. Hear more from him on why we’re so committed to expanding access to proactive care.

Today, we’re taking another step in making it easy to get proactive about your health. Introducing the Hims & Hers Multi-Cancer Test by Galleri®. By combining innovation from GRAIL and the ease of our platform, we’re giving you a way to screen for a signal for 50+ types of cancer in a single blood test. Our Chief Medical Officer, Dr. Pat Carroll, has spent decades as a family physician and has seen the difference earlier access to powerful technology can make for people everywhere. Hear more from him on why we’re so committed to expanding access to proactive care.

Hims & Hers Comms

85,537 просмотров • 7 месяцев назад

This morning we launched Labs, the easiest and most comprehensive way to get a real understanding of your health. Labs offers an annual subscription that tests up to 120 of the most critical biomarkers in your body, for just a few hundred dollars. From genetic cardiovascular numbers to metabolic syndrome, these are the biomarkers at the cutting edge of innovation. Data is helpful, but what comes next is what matters. Immediately when your results are in, our platform in partnership with thousands of doctors, nurses and providers will provide you with a specific analysis and action plan. Nutrition, movement, supplements, and personalized medication options. With over 1M square feet of pharmacy infrastructure, Hims & Hers doesn’t just test your health metrics, but unlocks your ability to actually improve them with access to precision treatments and care. This is the first offering with Hims & Hers I’m encouraging all of my family and friends to sign up for. The power of knowledge and early action is unmatched, and for the people we love there is no greater gift.

This morning we launched Labs, the easiest and most comprehensive way to get a real understanding of your health. Labs offers an annual subscription that tests up to 120 of the most critical biomarkers in your body, for just a few hundred dollars. From genetic cardiovascular numbers to metabolic syndrome, these are the biomarkers at the cutting edge of innovation. Data is helpful, but what comes next is what matters. Immediately when your results are in, our platform in partnership with thousands of doctors, nurses and providers will provide you with a specific analysis and action plan. Nutrition, movement, supplements, and personalized medication options. With over 1M square feet of pharmacy infrastructure, Hims & Hers doesn’t just test your health metrics, but unlocks your ability to actually improve them with access to precision treatments and care. This is the first offering with Hims & Hers I’m encouraging all of my family and friends to sign up for. The power of knowledge and early action is unmatched, and for the people we love there is no greater gift.

andrewdudum

136,674 просмотров • 10 месяцев назад

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 просмотров • 1 год назад

$HIMS $LLY $NVO 🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom We sat down with Geoff Cook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma A great episode with one of the best CEOs in the game - thanks again, Geoff! 00:00 - Why pharma needs DTC platforms 03:03 - Noom's 90% revenue growth 05:01 - Why Noom bought Tailor Made Compounding 07:29 - The case for vertical integration 08:56 - Compounded GLP-1s aren't going anywhere 16:48 - The Hims-Novo deal 19:08 - Noom's pitch to next-gen pharma 24:24 - Peptide market sizing 25:33 - Why GLP-1 users will buy peptides first 27:22 - Ten million potential peptide patients 👀 30:09 - When will legalization happen? 31:09 - Tracking the FDA green list 34:26 - Who wins when peptides go legal? 37:58 - Why Noom won't rush peptide launch 39:33 - Geoff's BPC-157 ski injury recovery 46:42 - Expanding at-home labs past 30 biomarkers 52:47 - Noom IPO coming?! Not financial, legal, or medical advice

$HIMS $LLY $NVO 🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom We sat down with Geoff Cook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma A great episode with one of the best CEOs in the game - thanks again, Geoff! 00:00 - Why pharma needs DTC platforms 03:03 - Noom's 90% revenue growth 05:01 - Why Noom bought Tailor Made Compounding 07:29 - The case for vertical integration 08:56 - Compounded GLP-1s aren't going anywhere 16:48 - The Hims-Novo deal 19:08 - Noom's pitch to next-gen pharma 24:24 - Peptide market sizing 25:33 - Why GLP-1 users will buy peptides first 27:22 - Ten million potential peptide patients 👀 30:09 - When will legalization happen? 31:09 - Tracking the FDA green list 34:26 - Who wins when peptides go legal? 37:58 - Why Noom won't rush peptide launch 39:33 - Geoff's BPC-157 ski injury recovery 46:42 - Expanding at-home labs past 30 biomarkers 52:47 - Noom IPO coming?! Not financial, legal, or medical advice

Hims House

55,711 просмотров • 5 месяцев назад

$LLY $NVO $HIMS 🚨 ELI LILLY SUED THE FDA TO GET RETATRUTIDE RECLASSIFIED AS A 'BIOLOGIC' "THIS IS THE MOST IMPORTANT EVENT" IN GLP-1s RIGHT NOW Bijan Salehizadeh: "Many years ago, the FDA said the definition of what is a biologic in the peptide world is more than 40 amino acids. Retatrutide is 39. That's just the facts." "And then there are 2 "linker" amino acids that... look, I went to medical school. Those aren't amino acids! They're like other things that [the amino acids] link onto to give it longer biological life in your body." "Lilly is claiming those two other entities are actually amino acids. So they proactively sued the FDA, Lilly did, and said, 'Retatrutide needs to be defined as a biologic.'" "Now, why are they so aggressive on this? Because if it's a biologic, you get 13 years of market exclusivity [versus only 9 years for a normal drug]... plus the price of biologics are typically into the upper thousands of month." "The peak sales estimates for retatrutide are ten billion or more a year. Some people call it the first trillion-dollar drug." Oral arguments are Sep 24 in Chicago. Bijan says he expects a ruling 3-4 months later:

$LLY $NVO $HIMS 🚨 ELI LILLY SUED THE FDA TO GET RETATRUTIDE RECLASSIFIED AS A 'BIOLOGIC' "THIS IS THE MOST IMPORTANT EVENT" IN GLP-1s RIGHT NOW Bijan Salehizadeh: "Many years ago, the FDA said the definition of what is a biologic in the peptide world is more than 40 amino acids. Retatrutide is 39. That's just the facts." "And then there are 2 "linker" amino acids that... look, I went to medical school. Those aren't amino acids! They're like other things that [the amino acids] link onto to give it longer biological life in your body." "Lilly is claiming those two other entities are actually amino acids. So they proactively sued the FDA, Lilly did, and said, 'Retatrutide needs to be defined as a biologic.'" "Now, why are they so aggressive on this? Because if it's a biologic, you get 13 years of market exclusivity [versus only 9 years for a normal drug]... plus the price of biologics are typically into the upper thousands of month." "The peak sales estimates for retatrutide are ten billion or more a year. Some people call it the first trillion-dollar drug." Oral arguments are Sep 24 in Chicago. Bijan says he expects a ruling 3-4 months later:

Hims House

25,432 просмотров • 1 месяц назад

Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): It’s fully approved in the US for one rare form of bladder cancer… but not for the common form most patients have. So even though the same drug is already FDA-approved and sitting in their files, he can’t use it off-label for other patients without insane one-patient-at-a-time paperwork, IRB delays, and individual FDA sign-off. Meanwhile, Saudi Arabia (with their own sophisticated FDA) reviewed the exact same 1.7 million pages of data and approved it for more cancers. His blunt takeaway: Cancer is a war against time. Patients are forced to fly to Saudi Arabia for access… or wait in bureaucratic limbo while the clock runs out. “I’m completely befuddled as to why this molecule… that stimulates your NK cells is not allowed to give to people who have low NK cells.” If a drug is already FDA-approved and sitting in their own files, why the insane barriers to using it for other patients who are dying? Is this protecting people… or protecting something else?

Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): It’s fully approved in the US for one rare form of bladder cancer… but not for the common form most patients have. So even though the same drug is already FDA-approved and sitting in their files, he can’t use it off-label for other patients without insane one-patient-at-a-time paperwork, IRB delays, and individual FDA sign-off. Meanwhile, Saudi Arabia (with their own sophisticated FDA) reviewed the exact same 1.7 million pages of data and approved it for more cancers. His blunt takeaway: Cancer is a war against time. Patients are forced to fly to Saudi Arabia for access… or wait in bureaucratic limbo while the clock runs out. “I’m completely befuddled as to why this molecule… that stimulates your NK cells is not allowed to give to people who have low NK cells.” If a drug is already FDA-approved and sitting in their own files, why the insane barriers to using it for other patients who are dying? Is this protecting people… or protecting something else?

Camus

51,195 просмотров • 7 месяцев назад

Veo 3 now on Leo. Sound on. 🔊 You heard right. Veo 3 – the most advanced video model available – is right here on Leo. Why is this big? ✨ Generate cinematic video with audio using just a prompt 🌍 Global access (no geo blocks) 🚀 Start from only $10/month and gen pricing as low as we can possibly make it – because everyone should get to play with this 💵 We've kept token rates as low as possible (effectively under $3 per video, depending on your plan) 🧰 Includes full access to creative suite This changes the game for creators, filmmakers, and anyone with a vision. Try it now 👉 #Veo3

Veo 3 now on Leo. Sound on. 🔊 You heard right. Veo 3 – the most advanced video model available – is right here on Leo. Why is this big? ✨ Generate cinematic video with audio using just a prompt 🌍 Global access (no geo blocks) 🚀 Start from only $10/month and gen pricing as low as we can possibly make it – because everyone should get to play with this 💵 We've kept token rates as low as possible (effectively under $3 per video, depending on your plan) 🧰 Includes full access to creative suite This changes the game for creators, filmmakers, and anyone with a vision. Try it now 👉 #Veo3

Leonardo.Ai

1,760,331 просмотров • 1 год назад

$HIMS Price Target in last 2 months & Eucalyptus✍️ Not Fianancial Advice! DYOR! Jefferies – lowered to $24.50 (from $25.50). Needham (Ryan MacDonald) – Buy, raised $30 → $35 BofA Securities (Allen Lutz) – Neutral, lowered $28 → $25 Leerink – Hold, $25 (maintain). Jun 3, 2026: Canaccord – Buy, $32 (maintain) JPMorgan (Cory Carpenter): Overweight, $35→ $33 Most of these analysts demand proof of re-accelerated growth, and refused to add Eucalyptus revenue in. Refused to build model/forecast on $HIMS scaling in 9 different countries. Q2 2026 will have 26-30% growth. Q3 and Q4 2026 will add Eucalyptue revenue in. But Eucalyptus entire year revenue belongs to $HIMS, but bears will say how much respect they have to reporting standard so they won't add it to Q1 Q2. That is fine, but as for investors u should be aware that Eucalyptus had an annualized revenue run-rate of ~$450M+ (as of early 2026) and now with with $HIMS growth will accelerate, where $HIMS raised guidance Full Year 2026: $2.8B – $3.0B did not include Eucalyptus. Eucalyptus is projected to have $600-$900M for FY2026(or $750m mid point) Q1 Q2 2026 adds around $120 and $150m estimated. $HIMS guidance for Q2 without Eucalyptus is $680-$700m Or consolidated $HIMS Q1 2026 $608.1m + $120m=$728.1m or 24.2% YoY Q2 2026 $680m(guide) + $150m=$800m or 52% YoY Q3 2026 $800m(est) +$200m= $1B or 67% YoY Q4 2026 $912m (est) + $280m= $1.192B or 93% YoY A. FY2027 when included all Eucalyptus revenue =$3.72B(conservative)-$4B(High end) or 58.2%-70.2% B. FY2027 when excluded Eucalyptus Q1 Q2 revenue =$3.48B(conseravtive)-$3.7B(High end) or 48%-57.4% Short sellers will say Eucalyptus is inorganic growth and they will only use B calculation above because they respect reporting standard. Or how they will wait until FY2027 so bears have time to exit at cheap share price. Eucalyptus is a strategic platform builder with synergy potential, not just a pure revenue add-on. The completion of Eucalyptus in June 2, 2026 marks a pivotal step in transforming Hims from a primarily U.S.-centric telehealth provider into a truly global consumer health platform. This deal accelerates Hims’ international footprint, giving it immediate leadership or strengthened positions in key markets and positioning the company to serve customers across approximately 9 countries through a combination of direct operations, local brands, and growing presence. Combined with Hims’ existing U.S. dominance, this creates a robust multi-continent platform focused on personalized, affordable care in areas like sexual health, hair loss, mental health, weight management (including GLP-1 offerings where regulated), and more. United States, United Kingdom, Australia, Canada, Germany, France, Ireland, Spain, Japan. $HIMS revenue growth internationally will accelerate growth and avoid US market concentration risk. Long term management guided $6.5 billion revenue and $1.3 billion Adjusted EBITDA by 2030. IMO this guidance will be reached by 2028/2029. Not Fianancial Advice! DYOR! Clip from :

$HIMS Price Target in last 2 months & Eucalyptus✍️ Not Fianancial Advice! DYOR! Jefferies – lowered to $24.50 (from $25.50). Needham (Ryan MacDonald) – Buy, raised $30 → $35 BofA Securities (Allen Lutz) – Neutral, lowered $28 → $25 Leerink – Hold, $25 (maintain). Jun 3, 2026: Canaccord – Buy, $32 (maintain) JPMorgan (Cory Carpenter): Overweight, $35→ $33 Most of these analysts demand proof of re-accelerated growth, and refused to add Eucalyptus revenue in. Refused to build model/forecast on $HIMS scaling in 9 different countries. Q2 2026 will have 26-30% growth. Q3 and Q4 2026 will add Eucalyptue revenue in. But Eucalyptus entire year revenue belongs to $HIMS, but bears will say how much respect they have to reporting standard so they won't add it to Q1 Q2. That is fine, but as for investors u should be aware that Eucalyptus had an annualized revenue run-rate of ~$450M+ (as of early 2026) and now with with $HIMS growth will accelerate, where $HIMS raised guidance Full Year 2026: $2.8B – $3.0B did not include Eucalyptus. Eucalyptus is projected to have $600-$900M for FY2026(or $750m mid point) Q1 Q2 2026 adds around $120 and $150m estimated. $HIMS guidance for Q2 without Eucalyptus is $680-$700m Or consolidated $HIMS Q1 2026 $608.1m + $120m=$728.1m or 24.2% YoY Q2 2026 $680m(guide) + $150m=$800m or 52% YoY Q3 2026 $800m(est) +$200m= $1B or 67% YoY Q4 2026 $912m (est) + $280m= $1.192B or 93% YoY A. FY2027 when included all Eucalyptus revenue =$3.72B(conservative)-$4B(High end) or 58.2%-70.2% B. FY2027 when excluded Eucalyptus Q1 Q2 revenue =$3.48B(conseravtive)-$3.7B(High end) or 48%-57.4% Short sellers will say Eucalyptus is inorganic growth and they will only use B calculation above because they respect reporting standard. Or how they will wait until FY2027 so bears have time to exit at cheap share price. Eucalyptus is a strategic platform builder with synergy potential, not just a pure revenue add-on. The completion of Eucalyptus in June 2, 2026 marks a pivotal step in transforming Hims from a primarily U.S.-centric telehealth provider into a truly global consumer health platform. This deal accelerates Hims’ international footprint, giving it immediate leadership or strengthened positions in key markets and positioning the company to serve customers across approximately 9 countries through a combination of direct operations, local brands, and growing presence. Combined with Hims’ existing U.S. dominance, this creates a robust multi-continent platform focused on personalized, affordable care in areas like sexual health, hair loss, mental health, weight management (including GLP-1 offerings where regulated), and more. United States, United Kingdom, Australia, Canada, Germany, France, Ireland, Spain, Japan. $HIMS revenue growth internationally will accelerate growth and avoid US market concentration risk. Long term management guided $6.5 billion revenue and $1.3 billion Adjusted EBITDA by 2030. IMO this guidance will be reached by 2028/2029. Not Fianancial Advice! DYOR! Clip from :

Mike

64,664 просмотров • 3 месяцев назад

Have you thought about studying in Europe/ Schengen countries with low tuition and also moving with your family as an international student? Then, you should consider Portugal 🇵🇹 Here are Top 5 reasons why Portugal should be on your radar! 🇵🇹🎓 📍Affordable Living: Compared to other Western European countries, Portugal offers a relatively low cost of living. Affordable rent, food, and transport make it easier to manage your budget while enjoying a great quality of life. 📍World-Class Universities: Portugal is home to top-ranked universities like the University of Porto and the University of Lisbon, offering a wide range of programs in English and Portuguese. The academic environment is strong, with plenty of research and internship opportunities. 📍Low Tuition Fee: Tuition fee for international students is as low as 1500-4000 euro, which can be paid in instalments as much as 5-10 times depending on the school. 📍Perfect Study-Work Balance: With stunning beaches, mild weather, and a relaxed lifestyle, Portugal allows you to balance your studies with outdoor activities, sports, and travel. You'll have plenty of time to explore during breaks! 📍Friendly International Community: Portugal attracts students from all over the world, creating a welcoming and diverse environment. Plus, English is widely spoken, so you'll feel right at home. Start your adventure in Portugal 🇵🇹

Have you thought about studying in Europe/ Schengen countries with low tuition and also moving with your family as an international student? Then, you should consider Portugal 🇵🇹 Here are Top 5 reasons why Portugal should be on your radar! 🇵🇹🎓 📍Affordable Living: Compared to other Western European countries, Portugal offers a relatively low cost of living. Affordable rent, food, and transport make it easier to manage your budget while enjoying a great quality of life. 📍World-Class Universities: Portugal is home to top-ranked universities like the University of Porto and the University of Lisbon, offering a wide range of programs in English and Portuguese. The academic environment is strong, with plenty of research and internship opportunities. 📍Low Tuition Fee: Tuition fee for international students is as low as 1500-4000 euro, which can be paid in instalments as much as 5-10 times depending on the school. 📍Perfect Study-Work Balance: With stunning beaches, mild weather, and a relaxed lifestyle, Portugal allows you to balance your studies with outdoor activities, sports, and travel. You'll have plenty of time to explore during breaks! 📍Friendly International Community: Portugal attracts students from all over the world, creating a welcoming and diverse environment. Plus, English is widely spoken, so you'll feel right at home. Start your adventure in Portugal 🇵🇹

Dr Oludayo Sokunbi

20,664 просмотров • 1 год назад

Pay Once. Get Lifetime Access to My Entire Library, Future Releases, 1-on-1 Coaching & Unlimited Support-Before This Deal Disappears Forever VIP Evergreen PLUS 1 Hour Consultation and 1 month Unlimited Text Support Everything I've EVER produced. Everything I'll EVER produce in the future. A Discord group to get your questions answered FAST. And Bunnies BEST SEX trifecta. Plus a BONUS of-1 month of Unlimited Text Support To get YOUR Game dialed in. (Unlimited Text Support includes a 1 hour initial Consultation and Unlimited Text Support for one Month) All for ONE price. Click Here for Immediate Access=> Every Book I've EVER written, every system I've EVER built, every book I WILL ever write, and every system I WILL ever build. Get it ALL for ONE LOW price. It will NEVER be priced like this again. Fort Worth Playboys EVERGREEN VIP BUNDLE = Every book Fort Worth Playboy has ever published, and every book Fort Worth Playboy will ever publish! PLUS THE UNLIMITED SEX SYSTEM (Bunny and FWPB collab) ALL the sex you could possibly handle with the girls YOU find most attractive GUARANTEED! PLUS ACCESS to our DISCORD server to get your questions answered FAST. PLUS Reduced pricing for future Courses, Webinars, Seminars, and Meetups! PLUS The added BONUS of Unlimited Text Support for One Month to get your GAME dialed in! ($199 Value) Due to the VALUE of this program steadily increasing, I can only justify offering 5 EVERGREEN VIP bundles at this insanely LOW price. Instantly download the entire current library, and get automatically emailed EVERY NEW TITLE in the future, without any further purchases! Pay once, reap the benefits for a lifetime! CURRENT COLLECTION (More titles ALWAYS in the works!) -The BEST of Chateau Heartiste Vol. 1 ($29.99 Value) -The BEST of Chateau Heartiste Vol. 2 ($29.99 Value) -The BEST of Chateau Heartiste Vol. 3 ($29.99 Value) -Younger Woman Game: Your Complete Guide to Age-Gap Dating by Chateau Heartiste ($19.99 Value) -Chicks Dig Jerks: Your Complete Guide to Asshole Game by Chateau Heartiste ($19.99 Value) -The Book of Dread: The Most Powerful Game Technique ($19.99 Value) -Alpha Male: The Ultimate How-To Guide by Chateau Heartiste ($29 Value) -BASIC TRAINING: The Basics of Game & Dating Etiquette ($24 Value) -BASIC TRAINING 2: The Basics of Game & Dating Etiquette ($24 Value) -Fort Worth Playboys Build Your Dating System ($29 Value) -Your Dating Rotation: A Comprehensive Guide to Building, Managing, and Maintaining Your Rotation of Girls ($29 Value) Indicators of Interest: How to KNOW if a Girl is Interested in You! ($19.99 Value) PLUS The DISCORD server is dedicated to getting YOU the answers to your burning questions as fast as possible. As well as trading BEST PRACTICES with other Men in the field as you are today. PLUS THE UNLIMITED SEX SYSTEM If you only had one life to live (and you do) would you say you’ve had all the sex you could want or handle? -THE UNLIMITED SEX SYSTEM BLUEPRINT to ENDLESS SEX ($48 Value) -Instant Self-Confidence with Women Handbook (2nd Edition) ($24 Value) -Magic Bullet Online Dating Profile Handbook (2nd Ed) ($24 Value) -BASIC TRAINING 1 and 2: The Basics of Game & Dating Etiquette ($34 Value)* -Fort Worth Playboys Build Your Dating System ($29 Value)* -Your Dating Rotation: A Comprehensive Guide to Building, Managing, and Maintaining Your Rotation of Girls ($29 Value)* -Fuck Like a Porn Star ($48 Value) -Make Her Squirt (Fuck Like a Porn Star Series, Book 2) ($24 Value) -Threesome (Book 3: Fuck Like a Porn Star Series) ($29 Value) -The Female Orgasm (Book 4: Fuck Like a Porn Star Series) ($24 Value) PLUS Bonus of 1 Hour Consultation and Unlimited Text Support (Unlimited Text Support includes a 1 hour initial Consultation and Unlimited Text Support for one Month, $199 Value) And MUCH MUCH more FOREVER! Currently material worth over $617+ $199 Unlimited Text Support AND every book I publish in the future for less than HALF that TODAY Click Here for Immediate Access=> P.s. Everything you ever needed and everything you could ever need to attract, seduce, bang, and maintain a relationship with the girls you desire MOST is within this comprehensive system. All available to YOU immediately and forever at one price. Click Here for Immediate Access=> If you aren't COMPLETELY SATISFIED with this UNLIMITED SEX SYSTEM I will gladly give you a COMPLETE REFUND no questions asked. I have EVERY reason and faith that this will give you the EDGE with the women YOU find MOST desirable. I can ONLY do 5 Bundles of this INSANE DEAL-when they're gone they're gone. Don't WAIT until it's TOO LATE to get your SYSTEM and get STARTED TODAY! FWPB P.s. Like I said don't wait until it's too late and the BONUS goes AWAY! Click Here for Immediate Access=> P.P.s. Everything you ever needed and everything you could ever need to attract, seduce, bang, and maintain a relationship with the girls you desire MOST is within this comprehensive system. All available to YOU immediately and forever at one price. Click Here for Immediate Access=>

FortWorthPlayboy

162,115 просмотров • 5 месяцев назад